Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates

BMC Pediatrics

Volumn 10, Issue , 2010, Pages

  van der Lugt, N Margreth ^a   Steggerda, Sylke J ^a   Walther, Frans J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; RIFAMPICIN; VANCOMYCIN; COAGULASE; ENZYME INHIBITOR;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NEWBORN; NEWBORN CARE; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PERSISTENT INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCAL BACTEREMIA; SYMPTOM; TERTIARY HEALTH CARE; THERAPY EFFECT; THROMBUS; TREATMENT OUTCOME; UREA BLOOD LEVEL; BACTEREMIA; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; ENZYMOLOGY; FOLLOW UP; GESTATIONAL AGE; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION;

BACTEREMIA; C-REACTIVE PROTEIN; COAGULASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; RETROSPECTIVE STUDIES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TREATMENT OUTCOME;

EID: 78349253114     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-10-84     Document Type: Article

References (27)

1. Tan TQ, Mason EO, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993, 37:2401-2406. 192398, 8285624.
2. Orsi GB, d'Ettorre G, Panero A, Chiarini F, Vullo V, Venditti M. Hospital-acquired infection surveillance in a neonatal intensive care unit. Am J Infect Control 2009, 37:201-203. 10.1016/j.ajic.2008.05.009, 19059676.
3. Wu JH, Chen CY, Tsao PN, Hsieh WS, Chou HC. Neonatal sepsis: a 6-year analysis in a neonatal care unit in Taiwan. Pediatr Neonatol 2009, 50:88-95. 10.1016/S1875-9572(09)60042-5, 19579754.
4. Auriti C, Maccallini A, Di LG, Di C, Ronchetti MP, Orzalesi M. Risk factors for nosocomial infections in a neonatal intensive-care unit. J Hosp Infect 2003, 53:25-30. 10.1053/jhin.2002.1341, 12495682.
5. Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: a 13-year hospital cohort study. Pediatrics 2009, 123:1314-1319. 10.1542/peds.2008-0656, 19403497.
6. Pullen J, Stolk LM, Degraeuwe PL, van Tiel FH, Neef C, Zimmermann LJ. Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. Ther Drug Monit 2006, 28:654-661. 10.1097/01.ftd.0000245382.79939.a4, 17038881.
7. Shama A, Patole SK, Whitehall JS. Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. Acta Paediatr 2002, 91:670-673. 10.1080/080352502760069098, 12162600.
8. Soraisham AS, Al-Hindi MY. Intravenous rifampicin for persistent staphylococcal bacteremia in premature infants. Pediatr Int 2008, 50:124-126. 10.1111/j.1442-200X.2007.02519.x, 18279222.
9. Watanakunakorn C, Guerriero JC. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 1981, 19:1089-1091. 181616, 7271276.
10. Varaldo PE, Debbia E, Schito GC. In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother 1983, 23:402-406. 184660, 6221692.
11. Bayer AS, Morrison JO. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984, 26:220-223. 284124, 6567464.
12. Tuazon CU, Lin MY, Sheagren JN. In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother 1978, 13:759-761. 352328, 666300.
13. Acar JF, Goldstein FW, Duval J. Use of rifampin for the treatment of serious staphylococcal and gram-negative bacillary infections. Rev Infect Dis 1983, 5(Suppl 3):S502-S506.
14. Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis 1981, 144:365-371.
15. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983, 5(Suppl 3):S407-S411.
16. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983, 5(Suppl 3):S428-S432.
17. Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis 1972, 125:486-490.
18. Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther Drug Monit 1986, 8:11-16. 10.1097/00007691-198603000-00003, 3961887.
19. Giedion A, Haefliger H, Dangel P. Acute pulmonary X-ray changes in hyaline membrane disease treated with artificial ventilation and positive end-expiratory pressure (PEP). Pediatr Radiol 1973, 1:145-152. 10.1007/BF00974058, 4589887.
20. Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant 2005, Philadelphia: Elsevier.
21. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986, 33:179-201.
22. Sie LT, van der Knaap MS, van Wezel-Meijler G, Taets van Amerongen AH, Lafeber HN, Valk J. Early MR features of hypoxic-ischemic brain injury in neonates with periventricular densities on sonograms. AJNR Am J Neuroradiol 2000, 21:852-861.
23. Volpe JJ. Neurology of the Newborn 2008, Philadelphia: Saunders.
24. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978, 92:529-534. 10.1016/S0022-3476(78)80282-0, 305471.
25. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW, . NECOSAD Study Group Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients--no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 2007, 22:3277-3284. 10.1093/ndt/gfm381, 17623721, NECOSAD Study Group.
26. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000, 67:360-367. 10.1067/mcp.2000.105353, 10801244.
27. Beardsall K, Dunger D. Insulin therapy in preterm newborns. Early Hum Dev 2008, 84:839-842. 10.1016/j.earlhumdev.2008.09.013, 18848411.